@prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . @prefix prodotto: . unitaDiPersonaleInterno:MATRICOLA18130 pubblicazioni:autoreCNRDi prodotto:ID23774 . @prefix prodottidellaricerca: . @prefix istituto: . istituto:CDS035 prodottidellaricerca:prodotto prodotto:ID23774 . @prefix modulo: . modulo:ID7731 prodottidellaricerca:prodotto prodotto:ID23774 . @prefix rdf: . @prefix retescientifica: . prodotto:ID23774 rdf:type retescientifica:ProdottoDellaRicerca , prodotto:TIPO1101 . @prefix rdfs: . prodotto:ID23774 rdfs:label "Upregulation of the immune system in primary hypercholesterolaemia: effects of atorvastatin theraphy (Articolo in rivista)"@en . @prefix xsd: . prodotto:ID23774 pubblicazioni:anno "2005-01-01T00:00:00+01:00"^^xsd:gYear ; pubblicazioni:doi "10.1111/j.1365-2796.2005.01488.x"^^xsd:string . @prefix skos: . prodotto:ID23774 skos:altLabel "
Sampietro T.; Bigazzi F.; Rossi G.; Dal Pino B.; Puntoni M.R.; Sbrana F.; Chella E.; Bionda A. (2005)
Upregulation of the immune system in primary hypercholesterolaemia: effects of atorvastatin theraphy
in Journal of internal medicine (Online)
"^^rdf:HTML ; pubblicazioni:autori "Sampietro T.; Bigazzi F.; Rossi G.; Dal Pino B.; Puntoni M.R.; Sbrana F.; Chella E.; Bionda A."^^xsd:string ; pubblicazioni:paginaInizio "523"^^xsd:string ; pubblicazioni:paginaFine "530"^^xsd:string ; pubblicazioni:numeroVolume "257"^^xsd:string . @prefix ns11: . prodotto:ID23774 pubblicazioni:rivista ns11:ID162042 ; pubblicazioni:note "In: J Int Medicine\\\",2005, 257,1-8"^^xsd:string ; pubblicazioni:pagineTotali "8"^^xsd:string ; skos:note "ISI Web of Science (WOS)"^^xsd:string , "ubMe"^^xsd:string ; pubblicazioni:affiliazioni "CNR Institute of Clinical Physiology, Pisa; Italy \nDepartment of Internal Medicine, University of Pisa, Pisa; Italy"^^xsd:string ; pubblicazioni:titolo "Upregulation of the immune system in primary hypercholesterolaemia: effects of atorvastatin theraphy"^^xsd:string ; prodottidellaricerca:abstract "Objectives. High levels of plasma high sensitivity Creactive protein (CRP), sensitive to therapy with statins, have been described in hyperchole sterolaemia. In vitro evidence shows that CRP activates the complement system, which, in turn, leads to an increased expression of ICAM-1. Our objectives were to verify whether primary hypercholesterolaemia (PHC) is associated with an upregulation of the inflammatory/immune response,\nand whether this is sensitive to atorvastatin. Methods and results. We examined the levels of sICAM-1, C3, C4 complement fractions in 48 patients with PHC, with (CAD group) or without (No-CAD group) coronary artery disease (CAD) in comparison with a group of 48 healthy controls. The two patient groups were studied before and after atorvastatin therapy. Both hypercholesterolaemic groups showed higher mean values of sICAM-1, C3 and C4 (P < 0.0001) when compared with the controls. The two groups of patients responded differently to atorvastatin therapy. After 3 months, the C3 levels normalized in both groups of patients (P < 0.02\ncompared with basal values); C4 was greatly reduced only in the CAD group (P < 0.01). After 12 months of therapy, in CAD group C3 mean levels were still significantly lower than baseline values (P < 0.01); a\nfurther decrease in the C4 values (P < 0.05 with respect to levels after 3 months of therapy) and also a substantial reduction in sICAM-1 values (P < 0.001 with respect to basal values) were observed. Conclusions. High plasma values of C3 and C4 in PHC cluster with high values of sICAM-1, distinguish subjects with CAD and could be used to monitor the anti-inflammatory effect of statin therapy in these patients."@en ; prodottidellaricerca:prodottoDi modulo:ID7731 , istituto:CDS035 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA18130 . @prefix parolechiave: . prodotto:ID23774 parolechiave:insiemeDiParoleChiave . ns11:ID162042 pubblicazioni:rivistaDi prodotto:ID23774 . parolechiave:insiemeDiParoleChiaveDi prodotto:ID23774 .